Blecher Gideon Adam, Chung Eric, Katz Darren, Kim Shannon Hee Kyung, Bailie John
School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia; Department of Urology, Alfred Health, Melbourne, Victoria, Australia; Department of Urology, Monash Health, Melbourne, Victoria, Australia.
Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia; AndroUrology Centre, St Andrew's War Memorial Hospital, Brisbane, Queensland, Australia.
Urology. 2022 Feb;160:109-116. doi: 10.1016/j.urology.2021.10.031. Epub 2021 Nov 21.
To assess sperm retrieval rates of Onco-Testicular Sperm Extraction (oncoTESE) in men with testicular tumors and coexisting severe spermatogenic impairment.
Multi-centre Australian wide retrospective review of oncoTESE procedures performed within the last 10 years. Patients were postpubertal adults having a testicular tumor requiring orchidectomy, with severe oligozoospermia or nonobstructive azoospermia. Ipsilateral testicular sperm extraction was performed following radical inguinal orchidectomy. A contralateral micro-testicular sperm extraction was performed if no sperm or insufficient amounts were initially achieved. Surgical sperm retrieval rates, live birth rates and post operative serum testosterone were recorded.
Four surgeons compiled a total 13 patients. The mean age was 34.9 years. Seven of 13 were germ cell tumor (GCT), 4 of 13 had non-GCT and 2 of 13 contained benign lesions. Twelve of 13 patients were azoospermic and 1 was severely oligozoospermic. Sperm was found in 6 of 7 GCT patients; 3 of 7 were found in the ipsilateral testis whilst the remaining 4 underwent contralateral micro-testicular sperm extraction; sperm was retrieved in 3 of 4. The respective mean pre and post orchidectomy testosterone was 12.0 vs 14.1nmol/L (GCT cohort). Cryopreserved sperm has been used in assisted reproduction in 2 of 13 patients, with median follow up of 38.7 months. Including use of both cryopreserved and fresh sperm, 6 pregnancies were achieved, including 5 healthy live births and 1 miscarriage.
OncoTESE appears feasible, with acceptable sperm retrieval and subsequent live birth rates, following assisted reproduction. Despite significant underutilisation in the Australian population, oncoTESE should be considered in the management for TC patients with severe oligozoospermia, or nonobstructive azoospermia.
评估患有睾丸肿瘤且并存严重生精功能障碍的男性患者经睾丸肿瘤精子提取术(oncoTESE)的精子获取率。
对过去10年内在澳大利亚范围内多中心进行的oncoTESE手术进行回顾性研究。患者为青春期后成年男性,患有需要睾丸切除术的睾丸肿瘤,伴有严重少精子症或非梗阻性无精子症。在根治性腹股沟睾丸切除术后进行同侧睾丸精子提取。如果最初未获取到精子或获取量不足,则进行对侧显微睾丸精子提取。记录手术精子获取率、活产率和术后血清睾酮水平。
4位外科医生共纳入13例患者。平均年龄为34.9岁。13例中有7例为生殖细胞肿瘤(GCT),13例中有4例为非GCT,13例中有2例为良性病变。13例患者中有12例为无精子症,1例为严重少精子症。7例GCT患者中有6例发现精子;7例中有3例在同侧睾丸中发现精子,其余4例进行了对侧显微睾丸精子提取,其中4例中有3例获取到精子。在GCT队列中,睾丸切除术前和术后睾酮的平均水平分别为12.0和14.1nmol/L。13例患者中有2例使用了冷冻保存的精子进行辅助生殖,中位随访时间为38.7个月。包括使用冷冻保存和新鲜精子,共实现6次妊娠,其中包括5例健康活产和1例流产。
oncoTESE似乎是可行的,在辅助生殖后具有可接受的精子获取率和随后的活产率。尽管在澳大利亚人群中oncoTESE的使用率明显不足,但对于患有严重少精子症或非梗阻性无精子症的睾丸癌患者,在治疗中应考虑采用oncoTESE。